Table 4.
Exploratory analysis of relationships between overall activity impairment outcomes and type of drug received
| Activity impairment measures | TCZ-SC group | csDMARDs-alone group | ||||||
|---|---|---|---|---|---|---|---|---|
| n | Standardized regression coefficient | 95% CI | P value | n | Standardized regression coefficient | 95% CI | P value | |
| Presenteeism (%) | 143 | −0.4861 | −0.6470, −0.3252 | < 0.0001 | 148 | −0.4328 | −0.5887, −0.2769 | < 0.0001 |
| Overall work impairment (%) | 143 | −0.4819 | −0.6437, −0.3202 | < 0.0001 | 148 | −0.3913 | −0.5491, −0.2336 | < 0.0001 |
| Activity impairment (%) | 143 | −0.6345 | −0.7747, −0.4943 | < 0.0001 | 148 | −0.6486 | −0.7876, −0.5096 | < 0.0001 |
| HAQ-DI | 143 | −0.4828 | −0.6415, −0.3241 | < 0.0001 | 148 | −0.1584 | −0.3360, 0.0201 | 0.0815 |
| EQ-5D | 143 | 0.3635 | 0.1960, 0.5311 | < 0.0001 | 148 | 0.3181 | 0.1446, 0.4916 | 0.0004 |
| DAS28-ESR | 143 | −0.3305 | −0.4950, −0.1661 | 0.0001 | 148 | −0.1802 | −0.3533, −0.0072 | 0.0414 |
| CDAI | 143 | −0.1950 | −0.3674, −0.0226 | 0.0270 | 148 | −0.1127 | −0.2819, 0.0564 | 0.1897 |
| SDAI | 143 | −0.2289 | −0.4003, −0.0576 | 0.0092 | 148 | −0.1113 | −0.2810, 0.0585 | 0.1971 |
| WFun | 143 | −0.3549 | −0.5266, −0.1832 | < 0.0001 | 148 | −0.1680 | −0.3353, −0.0007 | 0.0491 |
| K6 | 143 | −0.1895 | −0.3661, −0.0130 | 0.0355 | 148 | −0.1497 | −0.3216, 0.0222 | 0.0873 |
CDAI clinical disease activity index, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, EQ-5D EuroQol 5 dimension, HAQ-DI health assessment questionnaire disability index, K6 6-item Kessler psychological distress scale, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection, WFun work functioning impairment scale